Venus Remedies has received patent from Mexico for its novel antibiotic Potentox which has been granted by the Mexican Institute of Industrial Property (IMPI), the patent protects the composition of Potentox. The patent provides an exclusivity period for Potentox up to 2025.
Besides, the drug is also protected by patents from various other countries, including USA, India, Australia, New Zealand, South Korea, South Africa, Canada and Ukraine. Further, to take this novel antibiotic adjuvant entity to Mexico, the company is already holding talks with some big pharmaceutical companies over there for strategic tie-ups.
Potentox is an antibiotic adjuvant entity (AAE), a drug effective to treat cases of hospital-acquired pneumonia and febrile neutropenia infections, primarily caused by quinolones or aminoglycoside-resistant microbes.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
